Janssen-Cilag Ltd.
Guselkumab
Crohn's Disease
Countdown
336days
Phase 3 readout · Jun 8, 2027
What's at stake
Phase 3 trial results for Guselkumab in Crohn's Disease are due Jun 8, 2027. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· ClinicalTrials.gov
verified 15h ago
“CT.gov NCT06408935: Phase 3 trial, sponsor Janssen-Cilag Ltd., drug Guselkumab. Primary completion date 2027-06-08 (estimated).”